These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35982660)
1. Viral and Symptom Rebound in Untreated COVID-19 Infection. Deo R; Choudhary MC; Moser C; Ritz J; Daar ES; Wohl DA; Greninger AL; Eron JJ; Currier JS; Hughes MD; Smith DM; Chew KW; Li JZ; medRxiv; 2022 Aug; ():. PubMed ID: 35982660 [TBL] [Abstract][Full Text] [Related]
2. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection. Deo R; Choudhary MC; Moser C; Ritz J; Daar ES; Wohl DA; Greninger AL; Eron JJ; Currier JS; Hughes MD; Smith DM; Chew KW; Li JZ; Ann Intern Med; 2023 Mar; 176(3):348-354. PubMed ID: 36802755 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical Trial. Yang Z; Xu Y; Zheng R; Ye L; Lv G; Cao Z; Han R; Li M; Zhu Y; Cao Q; Ding Y; Wang J; Tan Y; Liu F; Wei D; Tan W; Jiang W; Sun J; Sun S; Shao J; Deng Y; Gao W; Wang W; Zhao R; Qiu L; Chen E; Zhang X; Wang S; Ning G; Xu Y; Bi Y JAMA Netw Open; 2024 Mar; 7(3):e241765. PubMed ID: 38477921 [TBL] [Abstract][Full Text] [Related]
11. The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls. Pandit JA; Radin JM; Chiang DC; Spencer EG; Pawelek JB; Diwan M; Roumani L; Mina MJ Clin Infect Dis; 2023 Jul; 77(1):25-31. PubMed ID: 36810665 [TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study. Han J; Bae S; Jung J; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Chang E; Kim SH Medicine (Baltimore); 2023 Sep; 102(39):e35094. PubMed ID: 37773854 [TBL] [Abstract][Full Text] [Related]
13. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ; Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363 [TBL] [Abstract][Full Text] [Related]
14. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study. Durstenfeld MS; Peluso MJ; Lin F; Peyser ND; Isasi C; Carton TW; Henrich TJ; Deeks SG; Olgin JE; Pletcher MJ; Beatty AL; Marcus GM; Hsue PY J Med Virol; 2024 Jan; 96(1):e29333. PubMed ID: 38175151 [TBL] [Abstract][Full Text] [Related]
19. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial. Chew KW; Moser C; Daar ES; Wohl DA; Li JZ; Coombs R; Ritz J; Giganti M; Javan AC; Li Y; Malvestutto C; Klekotka P; Price K; Nirula A; Fischer W; Bala V; Ribeiro RM; Perelson AS; Fletcher CV; Eron JJ; Currier JS; Hughes MD; Smith DM; medRxiv; 2021 Dec; ():. PubMed ID: 34981077 [TBL] [Abstract][Full Text] [Related]
20. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir. Wong GL; Yip TC; Lai MS; Wong VW; Hui DS; Lui GC JAMA Netw Open; 2022 Dec; 5(12):e2245086. PubMed ID: 36472873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]